Clinical Trial: Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Graft vs Host Disease
Study Type: INTERVENTIONAL
Official Title: Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Brief Summary:
Background:Chronic graft-versus-host disease (cGVHD) is an immune system disorder that can occur in people who have had a stem cell transplant.cGVHD can affect multiple organs and increase risk of disability and death.New treatments are needed to treat cGVHD after stem cell transplant.Objective:To test a drug (pacritinib) in people with moderate or severe cGVHD that has not responded to previous treatment.Eligibility:People aged 18 years and older with moderate or severe cGVHD that has not responded to 2 or more…
Read more